Distressed by pain, disability, and comorbidities many have to leave a normal working life in advance. Lipum intends to increase their quality of life and decrease the considerable health care and societal costs. They have identified a unique target for treatment of chronic inflammatory diseases. It is a protein denoted bile salt-stimulated lipase (BSSL) that acts by promoting recruitment of inflammatory and immune cells to the site of acute inflammation, which in the normal case helps to control the inflammation. The active ingredient will be a new biological drug, a unique monoclonal antibody targeting the BSSL molecule and inhibiting its action.